Albert David

₹793.85As of Sun 8 Nov 2026, 12:00 UTC

NSE:ALBERTDAVDHealthcare

Country India

PE (Fwd) —

TSR 10Y CAGR 8.80%

Div yield 0.63%

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.41

PE TTM —

TSR TTM (5.91%)

Mkt cap ₹4.572B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹881

10.98%

(61.07%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

63.39

132.15

30.14

(2.62)

2.60%

108.49%

(77.19%)

(108.69%)

Revenue₹B

3.416

3.625

3.458

3.336

8.95%

6.12%

(4.61%)

(3.52%)

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

3.336

Revenue₹B

—

3.135

3.416

3.625

3.458

3.336

3.452

1.56%

(3.52)

Revenue growth%

—

8.95

6.12

(4.61)

(3.52)

3.47

1.30

—

65.87

Gross margin%

—

63.34

63.68

65.13

66.37

65.87

65.88

65.13

(1.21)

Operating margin%

—

10.20

10.61

11.05

(1.11)

(1.21)

(1.19)

10.20

(0.45)

Net margin%

—

11.25

10.59

20.81

4.97

(0.45)

(0.47)

10.59

—

P/E ratio (avg)x

—

8.833

8.989

7.521

44.29

—

8.911

—

EV/EBITx

—

9.736

8.974

14.16

—

9.736

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

(2.62)

EPS₹

—

61.78

63.39

132.15

30.14

(2.62)

(2.83)

(21.28%)

—

(108.69)

EPS growth%

—

2.60

108.49

(77.19)

(108.69)

(8.19)

(37.30)

—

Bookvalue per sh₹

—

FCF per share₹

—

5.00

Dividend per sh₹

—

9.00

11.50

5.00

4.74

(13.67%)

—

0.63

Div yield (avg)%

—

1.65

1.58

1.16

0.37

0.64

0.60

1.16

—

Payout ratio%

—

14.57

14.20

8.70

16.59

—

14.38

—

5.707

Shares (diluted)M

—

5.707

◌5.707

—

Buyback yield%

—

◌—

—

D/E ratiox

—

4.531

Enterprise value₹B

—

3.114

3.252

5.673

7.619

4.451

4.531

9.34%

—

LT debt₹M

—

Peers (US$48.20M)

Cap (US$)

Valiant Laboratories…

67.15M

35.96x

Medicamen Biotech…

39.77M

37.01x

Aarey Drugs & Pharmace…

33.05M

85.43x

Labiana Health, S.A.

47.06M

13.82x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(1.581)

81.42

Own earn%

—

Sh yield%

0.63

0.90

Owners

Insiders/Inst%

12.48

2.61

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

4/5

Revenue growth years

2/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

−1–11

$1 testx

—

Incr. ROIC%

—

Albert David Limited manufactures and trades in pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs in India and internationally. It offers formulations for parenterals, oral/enterals, topical agents, aerosol, and vision care products.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹3.336B

1.56%

1.00×

Cost of revenue

₹1.139B

(0.23%)

0.93×

Operating expenses

₹2.238B

7.66%

1.26×

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available